公开(公告)号：EP1948620A2

公开(公告)日：2008-07-30

申请号：EP06825836.7

申请日：2006-10-12

申请人： Aventis Pharmaceuticals Inc.

发明人： LANGEVIN, Beverly ,  ORTON, Edward ,  SHERER, Daniel

IPC分类号： C07D239/46 ,  C07D239/47 ,  A61K31/505

CPC分类号： C07D239/47

摘要： The present invention is directed to the dihydrogen phosphate salt of 2-(3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid of Formula (III), a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of Formula (III), and a pharmaceutically acceptable carrier; and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like, by administering to said patient a pharmaceutically effective amount of the compound of Formula (III).

公开(公告)号：EP1948620B1

公开(公告)日：2013-03-20

申请号：EP06825836.7

申请日：2006-10-12

申请人： Aventis Pharmaceuticals Inc.

发明人： LANGEVIN, Beverly ,  ORTON, Edward ,  SHERER, Daniel

IPC分类号： C07D239/46 ,  C07D239/47 ,  A61K31/505

CPC分类号： C07D239/47

公开(公告)号：EP1044364B8

公开(公告)日：2008-01-02

申请号：EP98966876.9

申请日：1998-12-14

申请人： Aventis Pharmaceuticals Inc.

发明人： NAGULAPALLI, Vasant, K. ,  ORTON, Edward ,  AIREY, John, E. ,  KROLIKOWSKI, Paul, H.

IPC分类号： G01N24/08

CPC分类号： G01N24/00 ,  C08F8/12 ,  C08F8/14 ,  C08F8/18 ,  C08F8/20 ,  C08F8/26 ,  C08F8/30 ,  C08F8/34 ,  C08F2800/20 ,  C08F2810/20 ,  G01N24/08 ,  C08F8/10 ,  C08F112/14 ,  C08F212/08

摘要： This invention is directed to the use of F NMR to monitor and quantitate solid-phase reactions and fluorine-containing solid-phase reagents useful therefor.